Author: Dr David Bunton

CEO, REPROCELL Europe Ltd.

The gut microbiome in health and disease: the future for diagnosis and treatment of IBD and IBS?

A new method for distinguishing between IBD (inflammatory bowel disease) and IBS (irritable bowel syndrome) could be on the horizon following a publication by researchers from teams in the Netherlands and the US, who profiled the gut microbiome in stool samples from those with IBD, IBS and healthy controls.

Continue reading 

New publication by Roche on diarrheal toxicity induced by anti-HER2/3 combination therapy includes REPROCELL human fresh tissue data

A publication in Molecular Cancer Therapeutics has shed new light on the mechanisms by which anti-HER2/3 combination therapies can cause diarrhea.

Continue reading 

Do animal experiments translate to humans? A report by Elsevier and Bayer uses big data to shed new light on a hotly debated topic

The use of animals to predict the risk of adverse effects in humans is a long-standing debate within Pharma and also in society at large. Moreover, safety issues leading to clinical attrition remain a problem and a major financial drain on Pharma.

Continue reading